Guillaume Laconde (@glaconde34) 's Twitter Profile
Guillaume Laconde

@glaconde34

Medicinal chemist, PROTAC and #TPD technology
OXELTIS Scientist, oxeltis.com
Communication Deputy for the SCT, sct-asso.fr
Tweets = my own.

ID: 144825846

linkhttps://bit.ly/3T5VRJK calendar_today17-05-2010 11:58:53

4,4K Tweet

4,4K Followers

107 Following

Jacob Plieth (@jacobplieth) 's Twitter Profile Photo

$ARVN into phase 1 with a Kras G12D degrader, ARV-806. Let's hope it's better than $ALPMF ASP3082! clinicaltrials.gov/study/NCT07023…

Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

Structural evolution progress of orally bioavailable selective estrogen receptor degraders sciencedirect.com/science/articl…

Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

Construction of PROTAC-Mediated Ternary Complex Structure Distribution Profiles Using Extensive Conformational Search | Journal of Chemical Information and Modeling pubs.acs.org/doi/10.1021/ac…

Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

Research Progress in Targeting GSPT1: Molecular Glues, Bifunctional Degraders, and Antibody-Enabled Molecular Glues for Cancer Therapy | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

DCAF16-Based Covalent Degradative Handles for the Modular Design of Degraders | ACS Central Science pubs.acs.org/doi/10.1021/ac…

drug hunter (@drughunter_com) 's Twitter Profile Photo

Phosphotyrosine Mimetics Enable Selective STAT6 Degradation with AK-1690 | drughunters.com/3I877p2 Small molecule interference with the STAT6/IL-4/IL-13 signaling axis is gaining momentum, with multiple academic and industrial groups pursuing selective STAT6 inhibitors and

Phosphotyrosine Mimetics Enable Selective STAT6 Degradation with AK-1690 | drughunters.com/3I877p2

Small molecule interference with the STAT6/IL-4/IL-13 signaling axis is gaining momentum, with multiple academic and industrial groups pursuing selective STAT6 inhibitors and
Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

A Molecular Glue Approach to Control the Half-Life of CRISPR-Based Technologies | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

Design and Application of Cereblon-Recruiting Prodegraders | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

Structure-guided design of a methyltransferase-like 3 (METTL3) proteolysis targeting chimera (PROTAC) incorporating an indole–nicotinamide chemotype pubs.rsc.org/en/content/art…

Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

Chemical Proteomics Identifies RBBP7 as a New E3 Ligase Supporting Targeted Protein Degradation - Liu - Angewandte Chemie International Edition onlinelibrary.wiley.com/doi/10.1002/an…

Dan Nomura (@dannomura) 's Twitter Profile Photo

Cool paper from Monte Rosa on Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition | Science science.org/doi/10.1126/sc…

Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

drug hunter (@drughunter_com) 's Twitter Profile Photo

How to Use Drug Hunter to Improve Design Ideas Tuesday, July 22nd, 2025 8 AM PT | 11 AM ET | 5 PM CET One of the most common questions during the design process for new drug molecules is whether a particular structural motif appears in FDA-approved drugs or recent clinical

How to Use Drug Hunter to Improve Design Ideas 
Tuesday, July 22nd, 2025
8 AM PT | 11 AM ET | 5 PM CET

One of the most common questions during the design process for new drug molecules is whether a particular structural motif appears in FDA-approved drugs or recent clinical
Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

Discovery of a Novel EGFR PROTAC Degrader against C797S Resistance Mutation with Potent Antitumor Efficacy in NSCLC Treatment | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…